Abstract
The knowledge of metabolic profile of synthetic cannabinoids is important for the detection of drugs in urinalysis due to the typical absence or low abundance of parent cannabinoids in human urine. The fungus Cunninghamella elegans has been reported to be a useful tool for metabolism study and thus applicability to synthetic cannabinoid metabolism was examined. In this study, 8-quinolinyl 1-(5-fluoropentyl)-1H–indole-3-carboxylate (5F-PB-22), 8-quinolinyl 1-pentyl-1H-indole-3-carboxylate (PB-22), [1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11) and (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) were incubated with C. elegans and the metabolites were identified using liquid chromatography-quadrupole time-of-flight mass spectrometry. The obtained metabolites were compared with reported human metabolites to assess the suitability of the fungus to extrapolate human metabolism. 5F-PB-22 underwent dihydroxylation, dihydrodiol formation, oxidative defluorination, oxidative defluorination to carboxylic acid, ester hydrolysis and glucosidation, alone and/or in combination. The metabolites of PB-22 were generated by hydroxylation, dihydroxylation, trihydroxylation, dihydrodiol formation, ketone formation, carboxylation, ester hydrolysis and glucosidation, alone and/or in combination. XLR-11 was transformed through hydroxylation, dihydroxylation, aldehyde formation, carboxylation, oxidative defluorination, oxidative defluorination to carboxylic acid and glucosidation, alone and/or in combination. UR-144 was metabolised by hydroxylation, dihydroxylation, trihydroxylation, aldehyde formation, ketone formation, carboxylation, N-dealkylation and combinations. These findings were consistent with previously reported human metabolism except for the small extent of ester hydrolysis observed and the absence of glucuronidation. Despite the limitations, C. elegans demonstrated the capacity to produce a wide variety of metabolites including some major human metabolites of XLR-11 and UR-144 at high abundance, showing the potential for metabolism of newly emerging synthetic cannabinoids.
Similar content being viewed by others
Abbreviations
- CB1 :
-
Cannabinoid type 1
- CB2 :
-
Cannabinoid type 2
- C. elegans :
-
Cunninghamella elegans
- ESI:
-
Electrospray ionisation source
- 5F-PB-22:
-
8-quinolinyl 1-(5-fluoropentyl)-1H–indole-3-carboxylate
- 5F-PI-COOH:
-
5-fluoropentylindole-3-carboxylic acid
- HLM:
-
Human liver microsomes
- LC-QqQ:
-
Liquid chromatography-triple quadrupole
- LC-QTOF-MS:
-
Liquid chromatography-quadrupole time-of-flight mass spectrometry
- MS:
-
Mass spectrometry
- NMR:
-
Nuclear magnetic resonance
- PB-22:
-
8-quinolinyl 1-pentyl-1H-indole-3-carboxylate
- PI-COOH:
-
Pentylindole-3-carboxylic acid
- TMCP:
-
Tetramethylcyclopropyl
- UR-144:
-
(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
- XLR-11:
-
[1-(5-fluoropentyl)-1H–indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone
References
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2016: Trends and Developments. Luxembourg: Publications Office of the European Union 2016.
Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012;40(11):2174–84. doi:10.1124/dmd.112.047530.
Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta(9)-THC: mechanism underlying greater toxicity? Life Sci. 2014;97(1):45–54. doi:10.1016/j.lfs.2013.09.017.
Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid–related illnesses and deaths. N Engl J Med. 2015;373(2):103–7. doi:10.1056/NEJMp1505328.
Grigoryev A, Savchuk S, Melnik A, Moskaleva N, Dzhurko J, Ershov M, et al. Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B. 2011;879(15–16):1126–36. doi:10.1016/j.jchromb.2011.03.034.
Sobolevsky T, Prasolov I, Rodchenkov G. Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal. 2012;4(10):745–53. doi:10.1002/dta.1418.
Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, et al. Pentylindole/Pentylindazole synthetic cannabinoids and their 5-Fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5F-AB-PINACA. AAPS J. 2015;17(3):660–77. doi:10.1208/s12248-015-9721-0.
Diao X, Scheidweiler KB, Wohlfarth A, Pang S, Kronstrand R, Huestis MA. In vitro and in vivo human metabolism of synthetic cannabinoids FDU-PB-22 and FUB-PB-22. AAPS J. 2016;18(2):455–64. doi:10.1208/s12248-016-9867-4.
Castaneto MS, Wohlfarth A, Pang S, Zhu M, Scheidweiler KB, Kronstrand R, et al. Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. Forensic Toxicol. 2015;33(2):295–310. doi:10.1007/s11419-015-0275-8.
Vikingsson S, Green H, Brinkhagen L, Mukhtar S, Josefsson M. Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry. Drug Test Anal. 2016;8(9):950–6. doi:10.1002/dta.1896.
Sobolevsky T, Prasolov I, Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int. 2010;200(1–3):141–7. doi:10.1016/j.forsciint.2010.04.003.
Kavanagh P, Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V. Detection and tentative identification of urinary phase I metabolites of phenylacetylindole cannabimimetics JWH-203 and JWH-251, by GC–MS and LC–MS/MS. J Chromatogr B. 2013;934:102–8. doi:10.1016/j.jchromb.2013.07.005.
Zaitsu K, Nakayama H, Yamanaka M, Hisatsune K, Taki K, Asano T, et al. High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS. Int J Legal Med. 2015;129(6):1233–45. doi:10.1007/s00414-015-1257-4.
Sobolevsky T, Prasolov I, Rodchenkov G. Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue. Drug Test Anal. 2015;7(2):131–42. doi:10.1002/dta.1756.
Hutter M, Moosmann B, Kneisel S, Auwarter V. Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J Mass Spectrom. 2013;48(7):885–94. doi:10.1002/jms.3229.
Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, et al. First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem. 2013;59(11):1638–48. doi:10.1373/clinchem.2013.209965.
Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA. Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem. 2014;406(6):1763–80. doi:10.1007/s00216-014-7668-0.
Diao X, Scheidweiler KB, Wohlfarth A, Zhu M, Pang S, Huestis MA. Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. Forensic Toxicol. 2016;34:256–67. doi:10.1007/s11419-016-0312-2.
Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA. High-resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoid THJ-018 and its 5-Fluoro analog THJ-2201 after incubation in human hepatocytes. Clin Chem. 2016;62(1):157–69. doi:10.1373/clinchem.2015.243535.
Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, et al. First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J. 2013;15(4):1091–8. doi:10.1208/s12248-013-9516-0.
Wintermeyer A, Moller I, Thevis M, Jubner M, Beike J, Rothschild MA, et al. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem. 2010;398(5):2141–53. doi:10.1007/s00216-010-4171-0.
Takayama T, Suzuki M, Todoroki K, Inoue K, Min JZ, Kikura-Hanajiri R, et al. UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and alpha-PVT, by human liver microsome. Biomed Chromatogr. 2014;28(6):831–8. doi:10.1002/bmc.3155.
Jang M, Shin I, Yang W, Chang H, Yoo HH, Lee J, et al. Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake. Forensic Sci Int. 2014;244:85–91. doi:10.1016/j.forsciint.2014.08.008.
Vikingsson S, Josefsson M, Green H. Identification of AKB-48 and 5F-AKB-48 metabolites in authentic human urine samples using human liver microsomes and time of flight mass spectrometry. J Anal Toxicol. 2015;39(6):426–35. doi:10.1093/jat/bkv045.
De Brabanter N, Esposito S, Geldof L, Lootens L, Meuleman P, Leroux-Roels G, et al. In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122). Forensic Toxicol. 2013;31(2):212–22. doi:10.1007/s11419-013-0179-4.
De Brabanter N, Esposito S, Tudela E, Lootens L, Meuleman P, Leroux-Roels G, et al. In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom. 2013;27(18):2115–26. doi:10.1002/rcm.6673.
Schaefer N, Helfer AG, Kettner M, Laschke MW, Schlote J, Ewald AH, et al. Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: do they reflect patterns in humans? Drug Test Anal. 2016; doi:10.1002/dta.1995.
Maurer HH, Meyer MR. High-resolution mass spectrometry in toxicology: current status and future perspectives. Arch Toxicol. 2016;90(9):2161–72. doi:10.1007/s00204-016-1764-1.
Diao X, Huestis MA. Approaches, challenges, and advances in metabolism of new synthetic cannabinoids and identification of optimal urinary marker metabolites. Clin Pharmacol Ther. 2017;101(2):239–53. doi:10.1002/cpt.534.
Asha S, Vidyavathi M. Cunninghamella—a microbial model for drug metabolism studies—a review. Biotechnol Adv. 2009;27(1):16–29. doi:10.1016/j.biotechadv.2008.07.005.
Zhang D, Yang Y, Leakey JEA, Cerniglia CE. Phase I and phase II enzymes produced by Cunninghamella elegans for the metabolism of xenobiotics. FEMS Microbiol Lett. 1996;138(2–3):221–6. doi:10.1111/j.1574-6968.1996.tb08161.x.
Wang R-F, Cao W-W, Khan AA, Cerniglia CE. Cloning, sequencing, and expression in Escherichia coli of a cytochrome P450 gene from Cunninghamella elegans. FEMS Microbiol Lett. 2000;188(1):55–61. doi:10.1111/j.1574-6968.2000.tb09168.x.
Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S. Biotransformation of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella elegans. Forensic Sci Int. 2016;261:33–42. doi:10.1016/j.forsciint.2015.12.023.
Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67–74. doi:10.1016/S0163-7258(96)00140-4.
Wong YWJ, Davis PJ. Microbial models of mammalian metabolism: stereoselective metabolism of warfarin in the fungus Cunninghamella elegans. Pharm Res. 1989;6(11):982–7. doi:10.1023/a:1015905832184.
Olesen OV, Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology. 1997;55(5):235–43. doi:10.1159/000139533.
Zhang D, Evans FE, Freeman JP, Duhart B, Cerniglia CE. Biotransformation of amitriptyline by Cunninghamella elegans. Drug Metab Dispos. 1995;23(12):1417–25.
Hansson A, Thevis M, Cox H, Miller G, Eichner D, Bondesson U, et al. Investigation of the metabolites of the HIF stabilizer FG-4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry. J Pharm Biomed Anal. 2017;134:228–36. doi:10.1016/j.jpba.2016.11.041.
Guddat S, Fußhöller G, Beuck S, Thomas A, Geyer H, Rydevik A, et al. Synthesis, characterization, and detection of new oxandrolone metabolites as long-term markers in sports drug testing. Anal Bioanal Chem. 2013;405(25):8285–94. doi:10.1007/s00216-013-7218-1.
Tian J-L, Chen Y, Wang Y-X, Huang X-X, Sun X, Liu K-C, et al. Microbial transformation of methyl cyperenoate by Cunninghamella elegans AS 3.2028 and the antithrombotic activities of its metabolites. RSC Adv. 2016;6(113):112712–20. doi:10.1039/c6ra24332k.
Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S. Data on individual metabolites of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella elegans. Data Brief. 2016;7:332–40. doi:10.1016/j.dib.2016.02.039.
Choudhary MI, Khan NT, Musharraf SG, Anjum S, Atta Ur R. Biotransformation of adrenosterone by filamentous fungus, Cunninghamella elegans. Steroids. 2007;72(14):923–9. doi:10.1016/j.steroids.2007.08.002.
Nielsen LM, Holm NB, Olsen L, Linnet K. Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11. Drug Test Anal. 2016;8(8):792–800. doi:10.1002/dta.1860.
Kanamori T, Kanda K, Yamamuro T, Kuwayama K, Tsujikawa K, Iwata YT, et al. Detection of main metabolites of XLR-11 and its thermal degradation product in human hepatoma HepaRG cells and human urine. Drug Test Anal. 2015;7(4):341–5. doi:10.1002/dta.1765.
Jang M, Kim IS, Park YN, Kim J, Han I, Baeck S, et al. Determination of urinary metabolites of XLR-11 by liquid chromatography-quadrupole time-of-flight mass spectrometry. Anal Bioanal Chem. 2016;408(2):503–16. doi:10.1007/s00216-015-9116-1.
Scheidweiler KB, Jarvis MJ, Huestis MA. Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. Anal Bioanal Chem. 2015;407(3):883–97. doi:10.1007/s00216-014-8118-8.
Park M, Yeon S, Lee J, In S. Determination of XLR-11 and its metabolites in hair by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2015;114:184–9. doi:10.1016/j.jpba.2015.05.022.
Grigoryev A, Kavanagh P, Melnik A, Savchuk S, Simonov A. Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol. 2013;37(5):265–76. doi:10.1093/jat/bkt028.
Adamowicz P, Zuba D, Sekula K. Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int. 2013;233(1–3):320–7. doi:10.1016/j.forsciint.2013.10.005.
Schwartz H, Liebig-Weber A, Hochstätter H, Böttcher H. Microbial oxidation of ebastine. Appl Microbiol Biotechnol. 1996;44(6):731–5. doi:10.1007/bf00178610.
Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, et al. Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem. 2011;83(16):6381–8. doi:10.1021/ac201377m.
Rydevik A, Thevis M, Krug O, Bondesson U, Hedeland M. The fungus Cunninghamella elegans can produce human and equine metabolites of selective androgen receptor modulators (SARMs). Xenobiotica. 2013;43(5):409–20. doi:10.3109/00498254.2012.729102.
Zafar S, Yousuf S, Kayani HA, Saifullah S, Khan S, Al-Majid AM, et al. Biotransformation of oral contraceptive ethynodiol diacetate with microbial and plant cell cultures. Chem Cent J. 2012;6(1):109. doi:10.1186/1752-153x-6-109.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest..
Electronic supplementary material
ESM 1
(PDF 101 kb)
Rights and permissions
About this article
Cite this article
Watanabe, S., Kuzhiumparambil, U., Nguyen, M.A. et al. Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans . AAPS J 19, 1148–1162 (2017). https://doi.org/10.1208/s12248-017-0078-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-017-0078-4